Cabaletta BioCABA
Market Cap: $208M
About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Employees: 138
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
117% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $685K
8% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 49
2.76% less ownership
Funds ownership: 107.97% [Q1] → 105.21% (-2.76%) [Q2]
11% less funds holding
Funds holding: 158 [Q1] → 141 (-17) [Q2]
47% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 36
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
57% less capital invested
Capital invested by funds: $889M [Q1] → $380M (-$509M) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Wells Fargo Derek Archila 53% 1-year accuracy 16 / 30 met price target | 369%upside $20 | Overweight Maintained | 12 Aug 2024 |
Evercore ISI Group Gavin Clark-Gartner 64% 1-year accuracy 7 / 11 met price target | 252%upside $15 | Outperform Maintained | 12 Aug 2024 |
HC Wainwright & Co. Douglas Tsao 46% 1-year accuracy 48 / 104 met price target | 487%upside $25 | Buy Maintained | 9 Aug 2024 |
Cantor Fitzgerald Josh Schimmer 71% 1-year accuracy 41 / 58 met price target | 1,074%upside $50 | Overweight Reiterated | 21 Jun 2024 |
Stifel Ben Burnett 0% 1-year accuracy 0 / 3 met price target | 651%upside $32 | Buy Maintained | 17 Jun 2024 |